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  Cardiac Biomarker Release after Exercise in Healthy Children and 1 
Adolescents: A Systematic Review and Meta-analysis 2 
Running head: Cardiac biomarkers after exercise in youth 3 
2 
Abstract 4 
Purpose: We evaluated the impact of acute exercise and 24 h recovery on serum 5 
concentration of cardiac troponins (cTnT; cTnI) and NT-proBNP in healthy children 6 
and adolescents. We also determined the proportion of participants exceeding the upper 7 
reference limits (URL) and acute myocardial infarction (AMI) cut-off for each assay. 8 
Method: Web of Science, SPORTDiscus, MEDLINE, ScienceDirect and Scopus 9 
databases were systematically searched up to November 2017. Studies were screened, 10 
quality-assessed and data was systematically extracted and analyzed. Results: From 751 11 
studies initially identified, 14 met the inclusion criteria for data extraction. All three 12 
biomarkers were increased significantly after exercise. A decrease from post-exercise to 13 
24 h was noted in cTnT and cTnI, although this decrease was only statistically 14 
significant for cTnT. The URL was exceeded by a 76% of participants for cTnT, a 51% 15 
for cTnI and a 13% for NT-proBNP. Furthermore, the cut-off value for AMI was 16 
exceeded by 39% for cTnT and a 11% for cTnI. Post exercise peak values of cTnT were 17 
associated with duration and intensity (Q(3) = 28.3, P < .001) while NT-proBNP peak 18 
values were associated with duration (Q(2) = 11.9, P = .003). Conclusion: Exercise 19 
results in the appearance of elevated levels of cTnT, cTnI and NT-proBNP in children 20 
and adolescents. Post-exercise elevations of cTnT and NT-proBNP are associated with 21 
exercise characteristics.  22 
 23 
 24 
 25 
 26 
3 
Background 27 
Cardiac troponin T and I (cTnT and cTnI) are accepted indicators of myocyte necrosis 28 
and are considered sensitive markers of acute myocardial injury (MI) and infarction 29 
(AMI) (75). Serum cTnT and cTnI are elevated after irreversible heart muscle damage 30 
and levels peak during the subsequent days (1,60). The N-terminal fragment of the 31 
prohormone brain natriuretic peptide (NT-proBNP) is a marker accepted to reflect 32 
myocardial stretch (74), which is currently used to detect heart failure and 33 
asymptomatic left ventricular dysfunction (14,53) with the magnitude and duration of 34 
release dependent on the severity of stretch and stress (3). 35 
The lower detection limits of cTnT and cTnI assays have been greatly reduced in recent 36 
years (59) with new high sensitivity assays available for both biomarkers. These assays 37 
can detect the 99th percentile with a CV < 10% and measure cTn concentrations in at 38 
least a 50% of a healthy population at rest (59). Although the higher sensitivity of these 39 
assays enables better rates of true positive detection (40), a decline in specificity has 40 
been reported such that cTn appearance might be related to etiologies other than AMI 41 
(1,16,40). This can include physical exercise as a known non-pathological cause of cTn 42 
increase (1). 43 
Numerous investigations have described the serological release of cTnT, cTnI and NT-44 
proBNP after physical exercise and its kinetics (15,22,63). Contrary to an AMI-related 45 
release, cTn values normally peak within 2-5 h (cTnT) and 3-6 h (cTnI) post-exercise 46 
and then decrease returning to basal levels after 24 h of recovery in most participants 47 
(15,25). The differences between cTnT and cTnI peaks might be related to differences 48 
in their molecular weights (11). NT-proBNP release normally peaks immediately after 49 
exercise and remains elevated during the subsequent 72 h; and its clearance, that seems 50 
to take longer than cTn, has been related to a temporary reduction in kidney function 51 
4 
subsequent to exercise (9,11). These observations have important clinical implications, 52 
since the elevation of these cardiac biomarkers for several hours after physical exercise 53 
might be misinterpreted in physically active patients, admitted to the emergency 54 
department for chest pain of origins other than acute coronary syndrome and heart 55 
failure. 56 
The 99th percentile of a normal reference population, considered the upper reference 57 
limit (URL), is designated as the decision level for the diagnosis of MI for both general 58 
and paediatrics populations (34,75). In this respect, the reported 99th percentiles for 59 
children are lower than in adults for cTn and NT-proBNP (17,26,50), and both are used 60 
for clinical diagnostic (24). The magnitude of cTn and NT-proBNP post-exercise 61 
release, as well as the prevalence of data above clinical cut-offs have been extensively 62 
studied in healthy adults. Only a limited number of studies addressing the cardiac 63 
biomarker response to exercise in children and adolescents are currently available. 64 
Moreover, these studies are heterogeneous in terms of exercise exposure and often 65 
occur with small sample sizes and thus a limited statistical power. As a result, the 66 
association of cTn and NT-proBNP with exercise is currently controversial 67 
(7,29,44,52,61,65,67,69) and might be confounded with either individual as well as 68 
exercise characteristics. 69 
Based on studies with adult participants other individual characteristics, other than age, 70 
might influence cardiac biomarkers release. Sex differences in cTn and NT-proBNP are 71 
controversial (4,6,10,23,30,36,56,80). Previous exercise experience has been negatively 72 
associated with cTn release (10,21,47,76) while training load might be not associated 73 
with biomarker appearance (18,21,28,33,68,79). NT-proBNP is not associated with 74 
previous exercise experience either (62,68,77) while its association with training load 75 
remains controversial (18,28,43,61,62,64,65,68). Finally, fitness condition has not been 76 
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associated with cTn or NT-proBNP data (68,70). Exercise characteristics have also been 77 
studied as to their influence on cardiac biomarker release (15,71). Exercise intensity was 78 
mentioned as a predictor for cTn release while exercise duration has been correlated 79 
with both cTn and NT-proBNP data (8,9,12,64,68,83). Exercise mode and type have not 80 
been fully evaluated and any associations remain controversial (31,55,85). 81 
Previous systematic reviews and meta-analyses related to cardiac biomarker release 82 
after exercise have been focused on adult participants (15,66,71,82). To the best our 83 
knowledge no systematic review or meta-analysis has been published addressing the 84 
cardiac biomarkers response to exercise in children and adolescents. Considering that 85 
children and adolescents have a low cardiovascular risk (2), we selected this special 86 
group in order to get a “clean” background and preclude the potential effects of 87 
concealed cardiovascular diseases and get "pure" effect of exercise on cardiac 88 
biomarkers. Due to variations in sample size and the diversity of participant and 89 
exercise characteristics a systematic review with a meta-analysis could contribute to the 90 
current knowledge by synthesizing available data into single, more powerful estimates 91 
of effect. Moreover, secondary analysis might help to identify possible associations with 92 
individual and exercise characteristics that could explain a certain degree of 93 
heterogeneity between the current findings. 94 
In accordance with the PRISMA statement (41) the main objective of this study was to 95 
systematically review studies whose participants were healthy children and adolescents 96 
that were exposed to physical exercise and whose resting and post-exercise measures of 97 
cTnT, cTnI and NT-proBNP were described. A secondary objective was to analyse the 98 
moderator effects of a) age, b) pubertal status, c) sex, d) previous training (years), e) 99 
current training (h/week or km/week), f) exercise duration (minutes), g) exercise 100 
6 
intensity (average HR), h) maximum oxygen uptake (VO2max), and i) exercise mode on 101 
the pooled effects determined by the main objective. 102 
Methods 103 
Search strategy 104 
We searched Web of Science, SPORTDiscus, MEDLINE, ScienceDirect and Scopus 105 
databases between July 1, 2017 and November 30, 2017. A three-component additive 106 
search key (#A AND #B AND #C) was used with: #A, measurement; #B, intervention; 107 
and #C, population. All searches were restricted to title or abstract, and keywords were 108 
stated in English. Measurement was defined with the expression “cardiac biomarker*” 109 
OR Troponin OR TnT OR TnI OR cTn* OR hs-cTn* OR “N-terminal prohormone of 110 
brain natriuretic peptide” OR “NT-proBNP” OR “NT-pro-BNP”. Intervention was 111 
specified with: exercise OR sport* OR “physical activity” OR running OR marathon 112 
OR soccer OR swim* OR athletes. Finally, population was stated with “children OR 113 
adolescent* OR young”. 114 
Inclusion and exclusion criteria 115 
We selected observational or experimental studies with a repeated measures design. 116 
Participants (or a subset of them) must be under the age of 18, not have personal history 117 
or clinical evidences of cardiovascular disease and have a normal 12-lead 118 
electrocardiogram and/or echocardiogram at rest (72). Interventions of interest were 119 
those which involved exposure to physical exercise, including sport events and 120 
laboratory tests. We searched primarily for studies that reported serum cardiac 121 
biomarkers responses to exercise. Specifically, those which reported cTnT and/or cTnI 122 
and/or NT-proBNP before and after exercise. Inclusion criteria included the necessity to 123 
report some quantitative measure of location and variation (mean with standard 124 
deviation (sd); median with range; or median with inter quartile range) of the 125 
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biomarker’s value for a minimum of one time point post-intervention. Studies where 126 
participants were exposed to specific pharmacological or nutritional interventions were 127 
excluded and the remaining articles were included in our review. 128 
Data extraction 129 
Studies were inspected to gather the data for (where available): sample size, sex, 130 
maturational status, age, training status (years of previous experience, weekly hours of 131 
training, weekly km of training), VO2 max, performed exercise, exposure duration 132 
(minutes), average heart rate (surrogate of intensity) and absolute concentration of 133 
cTnT, cTnI or NT-proBNP before and after exercise. We also recorded the proportion 134 
of participants above the URL for each biomarker, and rate of participants above the 135 
cut-off for AMI for cTnT and cTnI. Outcomes reported as median [range] were 136 
transformed to mean (SD) using Wan et al.’s formulas (84). All concentrations were 137 
expressed in ng/L (75), and concentrations of cTn reported as “under limits of detection 138 
of 10 ng/L” were represented as 5 ng/L (12,48). 139 
Quality assessment 140 
We analysed the methodological quality of studies that met all inclusion criteria in order 141 
to detect possible methodological discrepancies that might explain a degree of 142 
heterogeneity between studies. In this sense, studies’ quality was assessed by two 143 
authors independently, filling the Quality Assessment Tool for before-after (Pre-Post) 144 
studies with no control group from the National Heart Lung and Blood Institute (42). 145 
This scale considers 12 binary items, which average scores each article from 0 146 
indicating high risk of bias, to 1 indicating low risk of bias (QATi). Discrepancies 147 
between assessors were resolved by a third author. 148 
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Statistical analysis 149 
All analyses were performed in R (54) using Viechtbauer’s “metafor” package (81). 150 
Random effects meta-analyses were conducted by biomarker (cTnT, cTnI and NT-151 
proBNP) using the following estimates: the baseline concentration, the peak 152 
concentration, the concentration at 24 h, the absolute mean difference between baseline 153 
and peak concentrations, the absolute mean difference between baseline and 154 
concentration after 24 h recovery, the absolute mean difference between peak 155 
concentrations and concentrations at 24 h post exercise, the rate of participants whose 156 
peak concentration exceeded the assay URL and the rate of participants exceeding the 157 
cut-off for AMI. Rates were log-transformed for statistical comparisons and estimates 158 
were then back transformed for ease of interpretation. Heterogeneity was measured with 159 
Cochrane’s Q statistic and I2 values (19). We assessed publication bias using Egger’s 160 
regression test for funnel plot asymmetry (5,57). Subgroup analyses were conducted 161 
when heterogeneity was significant to assess the possible influence of exercise mode, 162 
age, intensity and duration on the absolute mean difference between baseline and peak 163 
concentrations. In addition, when data was available, we investigated for the possible 164 
influence of Tanner stage, sex, VO2max, years of previous training, weekly hours of 165 
training and weekly km of training, regardless of exercise mode, age, intensity and 166 
duration. Outcome multiplicity from the same groups (12) was controlled introducing a 167 
study identification as a random effect (51,81). Measures are expressed as mean ± 95% 168 
confidence intervals (CI) unless otherwise stated and we considered statistically 169 
significant differences when P < .05. 170 
Results 171 
The search process appears outlined in Figure 1. Fourteen studies met the 172 
inclusion/exclusion criteria that included 21 groups covering a total sample of 336 173 
9 
participants (72 females) who had a mean age of 15.1 ± 2.3 years (12,13,49,76–174 
78,20,27,30,38,39,46–48). Two studies provided complete data from more than one 175 
subgroups contributing with different estimates by sex (27,78) or Tanner stage (30), 176 
which were treated as different units for the analysis. One study provided four outcome 177 
measurements from the same group at different exposures (12), which were controlled 178 
for multiplicity within the models (51,81). Interventions were based on five different 179 
modalities: in nine studies participants ran [three treadmill protocols (45 to 90 min) 180 
(13,46,77), five half marathons (12,27,47,48,76) and one full marathon (78)], in two 181 
studies basketball was employed (38,49), in one a soccer match (20), in one study 182 
participants swam for 60 min (30) and one included a set of table tennis exercises (39). 183 
Table 1 shows the number of groups available for each comparison (k) as well as their 184 
respective pooled effect sizes. 185 
**Figure 1** 186 
Figure 1. Flowchart for study inclusion and exclusion stages.187 
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Table 1. Estimated pooled effect sizes (95% CI) by biomarker. 189 
 K Pooled Effect Size Z p(Z) Q p(Q) I 2 
Cardiac Troponin T        
  Mean baseline (ng/L) 16 5 (4, 6) 11.84 < .001 206.47 < .001 98.7% 
  Mean peak (ng/L) 14 144 (83, 205) 4.65 < .001 105.78 <.001 96.5% 
  Mean at 24 h (ng/L) 9 11 (5, 16) 3.86 < .001 146.52 < .001 98.2% 
  Dif. Peak - Pre (ng/L) 14 139 (79, 198) 4.53 < .001 102.72 < .001 96.4% 
  Dif. 24 h - Peak (ng/L) 7 -89 (-147, -32) -3.04 .002 33.85 < .001 93% 
  Dif. 24 h - Pre (ng/L) 9 7 (1, 12) 2.5 .01 87.22 < .001 96.3% 
  MI threshold IR 18 .76 (.66, .87) -3.83 < .001 27.86 .047 13.5% 
  AMI threshold IR 14 .39 (.26, .6) -4.38 < .001 39.1 < .001 75.4% 
Cardiac Troponin I        
  Mean baseline (ng/L) 7 16 (10, 22) 5.15 < .001 89.67 < .001 96.4% 
  Mean peak (ng/L) 5 248 (17, 478) 2.1 .04 61.42 < .001 99 % 
  Mean at 24 h (ng/L) 7 38 (19, 56) 4.05 < .001 348.01 < .001 97.7% 
  Dif. Peak - Pre (ng/L) 5 228 (6, 450) 2.01 .04 54.53 < .001 98.9% 
  Dif. 24 h - Peak (ng/L) 5 -199 (-404, 5) -1.91 .06 42.56 < .001 98.2% 
  Dif. 24 h - Pre (ng/L) 7 21 (8, 33) 3.23 .001 100.97 < .001 93.2% 
  MI threshold IR 7 .51 (.32, .81) -2.85 .004 16.74 .01 60.5% 
  AMI threshold IR 4 .11 (.05, .24) -5.4 < .001 3.41 .33 24.4% 
NT-proBNP        
  Mean baseline (ng/L) 6 77 (14, 140) 2.38 .02 217.98 < .001 99.5% 
  Mean peak (ng/L) 6 106 (17, 195) 2.34 .02 288.19 < .001 99.5% 
  Mean at 24 h (ng/L) 4 83 (0*, 182) 1.63 .10 173.89 < .001 99.6% 
  Dif. Peak - Pre (ng/L) 6 20 (2, 38) 2.20 .03 13.64 .02 79.2% 
  Dif. 24 h - Peak (ng/L) 4 -2 (-11, 7) -0.48 .63 7.26 .06 0.1% 
  Dif. 24 h - Pre (ng/L) 4 4 (-8, 28) 1.55 .44 0.65 .88 0% 
  MI threshold IR 6 .13 (.04, .44) -3.32 < .001 18.02 .003 74.1% 
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Note: Estimated effects for Incidence Rates (IR) were back transformed for easier interpretation. 190 
* Mathematically negative and truncated to 0 avoiding values outside the parameter space. 191 
Quality assessment and risk of publication bias 192 
Studies had a mean quality score of .61 (SD = .07). Pre-specification of sample 193 
eligibility criteria, enrollment of all eligible participants and sample size calculation 194 
were rated as high risks of bias in all studies. Other concurrent items rated as high risk 195 
of bias were blinding of outcome assessors, controlling for confounding variables in 196 
statistical analysis, reporting main effect of time with p values, and validity and 197 
reliability of outcome measures, in 12, 9, 3 and 1 cases, respectively. On the other hand, 198 
Egger’s regression test was significant for all three biomarkers cTnT, cTnI and NT-199 
proBNP (P < .001), suggesting that current literature was still unrepresentative of the 200 
population of completed studies. 201 
Cardiac troponin T 202 
Participants had an overall cTnT concentration at baseline of 5 ng/L (4 ng/L to 6 ng/L). 203 
This concentration was increased (P < .001) after 2-5 h, reaching a peak of 144 ng/L (83 204 
ng/L to 205 ng/L). Finally, 24 h after exercise cTnT was reduced (P < .002) with a 205 
pooled concentration of 11 ng/L (5 ng/L to 16 ng/L), which was slightly higher than at 206 
baseline (P  = .01) (Figure 2). All three pooled concentrations as well as their differences 207 
were heterogeneous between studies (P < .001 in all comparisons). Overall 76% (66% 208 
to 87%, P < .001) of participants had a cTnT peak above the assays URL, and a 39% 209 
(26% to 60%, P < .001) exceeded the cut-off for AMI. Again, both rates, for MI and for 210 
AMI, were heterogeneous between studies (P = .047 and P < .001, respectively). 211 
In the subgroups analyses, cTnT was measured in four exercise modes, namely half 212 
marathon, treadmill running, table tennis and swimming. Exercise mode, available in k 213 
= 14 units with a total of n = 193 participants, had a main effect on cTnT increase-to-214 
12 
peak (Q(3) = 9.98, P = .02). Post-hoc analysis revealed that after a half marathon and 215 
treadmill run cTnT increases were higher than after intermittent table tennis and 216 
swimming (P < .001 and P = .004, respectively). Multiple regression with exercise 217 
mode as a random effect (k = 11, n = 138), revealed that age had a negative association 218 
(P <  .001) while intensity and duration were positively associated (P < .001 and P = 219 
.003, respectively) with cTnT increase (Q(3) = 28.3, P < .001). Moreover, participants’ 220 
VO2max correlated negatively with cTnT increase (k = 7, n = 60, P = .04). We did not 221 
find associations between cTnT increase and sex (k = 11, n = 138, P = .3), Tanner stage 222 
(k = 4, n = 63, P = .5), years of previous training (P = .16) or weekly km of training (k = 223 
10, n = 110, P = .32). 224 
**Figure 2** 225 
Figure 2. Estimated kinetics by biomarker before, at peak value and 24 h after exercise, 226 
with their respective 95% IC. Note: a = significant increase; b = significant decrease; c 227 
= higher than at baseline. 228 
Cardiac troponin I 229 
The pooled baseline concentration for cTnI was 16 ng/L (10 ng/L to 22 ng/L). After 3-6 230 
h of exercise exposure participants increased this concentration (P = .04) up to a peak of 231 
248 ng/L (17 ng/L to 478 ng/L). After 24 h recovery, this reduced to 38 ng/L (19 ng/L 232 
to 56 ng/L) which was not statistically different from the estimated peak concentration 233 
(P = .06) (Figure 2). However, all three pooled concentrations as well as their 234 
differences were heterogeneous between studies (P < .001 in all comparisons). The 235 
proportion of participants with cTnI above the URL was 51% (32% to 81%) and the rate 236 
exceeding the cut-off for AMI was 11% (5% to 24%). The rate for MI was 237 
heterogeneous (P = .01) while the rate for AMI was not (P = .33) between individual 238 
studies. 239 
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In the subgroup analysis, cTnI was measured in four exercise modes, namely half 240 
marathon, basketball, table tennis and soccer. The cTnI increase to peak did not differ 241 
between exercise modes (k = 5, n = 83, Q(4) = 4.75, P = .31), and did not either in a 242 
multiple comparison (k = 4, n = 61) at different ages (P = .33), intensities (P = .6) or 243 
durations (P = .31). In addition, we did not find differences due to years of training (k = 244 
3, n = 33, P = .37) or participants’ VO2max (k = 3, n = 33, P = .54). Tanner stage and 245 
weekly training load data were not available to be modelled. 246 
N-terminal prohormone Brain Natriuretic Peptide 247 
The pooled baseline concentration for NT-proBNP corresponded to 77 ng/L (14 ng/L to 248 
140 ng/L). This concentration was increased immediately after exercise (P = .03) 249 
achieving a peak of 106 ng/L (17 ng/L to 195 ng/L). Finally, 24 h after exercise NT-250 
proBNP concentration did not differ from its peak (P = .63) or baseline (P =  .44) with 251 
an estimate of 83 ng/L (0 ng/L to 182 ng/L) (Figure 2). All three concentrations were 252 
heterogeneous (P < .001). The rate of participants with NT-proBNP concentration 253 
above the URL was 13% (4% to 44%, P < .001), and studies were heterogeneous (P = 254 
.003). 255 
In the subgroup analysis, NT-proBNP was present in four different exercise modes, 256 
namely half marathon, treadmill running, swimming and soccer. Exercise mode, had a 257 
main effect on the NT-proBNP post exercise increase (k = 6, n = 101, Q(4) = 25.06, P  < 258 
.001). Post-hoc comparisons revealed that the higher NT-proBNP increases were related 259 
with soccer (estimated increase of 83 ng/L, 95%CI from 34 ng/L to 131 ng/L, P  < .05) 260 
followed by half marathon (estimated increase of 59 ng/L, 95%CI from 12 ng/L to 105 261 
ng/L, P  = .01) and finally followed by swimming (estimated increase of 11 ng/L, 262 
95%CI from 3 ng/L to 18 ng/L, P  = .006), with no differences in the mode of treadmill 263 
running (P =.9). Moreover, in a multiple regression with exercise mode as a random 264 
14 
effect (k = 4, n = 62), duration had a positive association with the estimate (P < .001) 265 
while age (P = .34) and intensity (P = .37) were not associated with NT-proBNP (Q(2) = 266 
11.9, P = .003). Finally, we did not find differences in NT-proBNP for sex (k = 4, n = 267 
62, P = .3), Tanner stage (k = 3, n = 50, P  = .6) and years of previous training (k = 4, n = 268 
62, P = .5). VO2max, and weekly training load data were not available to be modelled. 269 
Discussion 270 
The main purpose of this systematic review and meta-analysis was to estimate how 271 
exercise modulated the blood concentration of cTnT, cTnI and NT-proBNP in children 272 
and adolescents. Overall, this review found: 1) all three biomarkers were significantly 273 
elevated after exercise; 2) a decrease from peak values after 24 h recovery was only 274 
significant for cTnT; 3) the rate of participants exceeding the biomarkers’ URL were 275 
76% for cTnT, 51% for cTnI and 13% for NT-proBNP; 4) the rate of participants 276 
exceeding the cut-off value for AMI were 39% for cTnT and 11% for cTnI; 5) 277 
individual variability was observed between studies; and 6) exercise duration influenced 278 
both cTnT and NT-proBNP while intensity influenced only cTnT. Despite these 279 
findings, the quality assessment of studies together with the analysis for publication bias 280 
revealed that current studies have a fair degree of quality with limited bias. 281 
Cardiac troponin T and I 282 
Our results indicate that cTn release in children and adolescents is inherent to physical 283 
exercise. Data reflect a fast increase of cTnT during the early hours of recovery, with 284 
close to complete recovery to baseline at 24 h. Similar results were appreciable for cTnI, 285 
although statistical power was limited and lead to only marginally significant 286 
differences between peak and 24 h values. Such observations suggest that cTn kinetics 287 
in children and adolescents during a 24 h recovery are comparable with the observed in 288 
adults (15,25). Our results coincide with previous research observing the highest cTnT 289 
15 
and cTnI concentrations about 2-3 and 3-5 h post exercise, respectively (15,25). Based 290 
upon the foregoing, when repeated blood sampling are not possible, single samples 291 
taken within such interval might detect concentrations close to the kinetics peak. 292 
The current data suggest that, as in the case of adults (31,33), there is a marked 293 
individual variability regarding the exercise induced release of cTn, with a high 294 
proportion of participants with values exceeding the URL for MI and AMI. As 295 
evidenced in controlled studies with adolescents (12) and adults (68), cTnT variability 296 
could be partially explained by exercise intensity and duration, what likely reflects an 297 
impact of exercise volume on cardiac work. We also observed a higher cTnT release in 298 
the younger participants, and this could explain that the proportion of participants 299 
exceeding the URL in our study is higher than the reported by a recent meta-analysis 300 
without age restrictions (66). This would suggest a role for maturity mediating the post 301 
exercise cTn release. However, direct comparisons of the release of cTn after exercise 302 
in adults and adolescents have disclosed contradictory findings (30,38,77). Moreover, 303 
with the scarce data currently available we did not find any association between cTnT 304 
release and pubertal status. At all events, associations with pubertal status require 305 
further investigation. Running seems to induce higher cTnT releases than other modes 306 
as it was noticed in a previous meta-analysis based on adult participants (71); 307 
nevertheless, such assertion is complex to verify through direct comparisons. Although 308 
we observed lower cTnT releases in participants with greater VO2max, we could not 309 
corroborate whether the cTnT increase is mediated by current training or training 310 
history. It was not evident whether there were any sex differences in the cTn release. 311 
This coincides with previous studies in adults which reported a limited influence of sex 312 
and training history on the release of cTn (4,27,30,32,33,38,78). The scarce number of 313 
16 
studies did not allow to explain the between-subjects variability regarding the release of 314 
cTnI. 315 
N-terminal prohormone Brain Natriuretic Peptide 316 
An increase in NT-proBNP immediately after exercise was confirmed without a 317 
significant reduction within the 24 h recovery period that supports past research with 318 
adults (32,37). NT-proBNP may have a longer clearance period that cTn possibly 319 
extended to 72 h (9,11). In this regard, it has been suggested that BNP may play an 320 
important role in homeostasis during the transition of the circulation from children to 321 
maturity as a marker of myocardial growth (73). This might reflect an early myocardial 322 
adaptation to the intense training stimulus in children and adolescents. In either case, 323 
these possibilities require further study. 324 
We noted that NT-proBNP changes with exercise were lower than the observed in cTn. 325 
Therefore, the proportion of participants exceeding the URL of NT-proBNP was lower 326 
than the reported in studies with adults (11,63). These differences might be associated 327 
with age. However, neither our analysis nor previous studies comparing directly 328 
adolescents with adults found NT-proBNP differences for age and pubertal status 329 
(30,77). It is therefore plausible to think that these differences might be related to 330 
exercises with less duration in studies conducted with adolescents compared with their 331 
equivalents with adults. Our results confirm indeed that in adolescents the release of 332 
NT-proBNP is largely associated with exercise duration, as it was reported previously in 333 
studies with adults (67,68). Given the close relationship between pre- and post-exercise 334 
values (32,33), baseline differences between studies might explain part of the 335 
differences we observed across NT-proBNP peak values depending on the exercise 336 
mode. Our results also confirmed that as in adults (4,30,32,33,67,68) exercise intensity, 337 
17 
training, fitness and sex have limited influence on the release of NT-proBNP with 338 
exercise. 339 
Clinical implications 340 
A cardiac biomarker release was observed in most of the participants in all included 341 
studies, despite a certain degree of between-study variability. Importantly, this analysis 342 
shows that in children and adolescents, the factors mediating cardiac biomarkers after 343 
exercise as well as their kinetics, are comparable with the observed in previous studies 344 
in adults and differ from the observed after MI and AMI (74,75). It has been suggested 345 
that this reflects a reversible cellular process triggered by a normal physiological 346 
response to exercise (9,45,58,62). Likewise, the increase of cTn might reflect an 347 
increased rate and force of cardiac contraction during exercise that causes transient 348 
membrane damage and enables cystolic cTn to pass into circulation (69). On the other 349 
hand, a release of NT-proBNP from the ventricular cardiomyocytes might reflect a 350 
volume overload and cardiac wall stretch during exercise (11). Furthermore, some 351 
authors suggested that the use of the general population values as a reference might not 352 
be appropriate for adult athletes being evaluated for medical conditions using blood 353 
indices of cardiac biomarkers. This has prompted the reflection that cardiac biomarkers 354 
values might be stratified according to the physical activity of the adult subjects for 355 
improving the clinical usefulness of the biomarker (35). In this sense, our analysis 356 
extends this to children and adolescents, and suggests that when evaluating cTnT, cTnI 357 
and NT-proBNP in emergency settings, detailed information regarding any recent 358 
exercise should be obtained (38).  359 
Limitations 360 
The main limitation of this systematic review and meta-analysis derives from the 361 
incomplete data provided by a range of heterogeneous studies. Moderator analyses were 362 
18 
performed with reduced numbers that decreased statistical power. This lack of statistical 363 
power might explain some non-significant results such as the inconclusive decrease in 364 
cTnI within a 24 h post-exercise recovery. We did not incorporate assay precision to our 365 
meta-analysis which could have explained certain degree of the study-to-study 366 
heterogeneity (71). Finally, we found differences between studies regarding when peak 367 
concentrations were taken or noted. In conclusion, more research should be conducted 368 
with children and adolescents analyzing such covariate parameters. 369 
Conclusion 370 
In conclusion, cardiac biomarkers in children and adolescents are significantly increased 371 
form rest to post-exercise with the URL exceeded by a 76% of participants for cTnT, a 372 
51% for cTnI and a 13% for NT-proBNP and the cut-off value for AMI exceeded by 373 
39% for cTnT and a 11% for cTnI. Finally, we confirmed that the cTnT release is 374 
mainly associated with exercise duration and intensity, while the NT-proBNP release 375 
remains influenced only by exercise duration. 376 
377 
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